Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for preventing or treating hearing loss

A technology for hearing disorders and cilostazol, which is applied in the field of pharmaceutical compositions for preventing or treating hearing disorders, and achieves the effects of treating noise-induced hearing disorders or ototoxic hearing disorders and inhibiting apoptosis

Active Publication Date: 2014-12-24
SK CHEM CO LTD
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, in order to prevent ototoxic hearing impairment, sulfhydryl drugs such as sodium thiosulfate; calcium channel blockers such as N-acetylcysteine, D- and L-methionine, and flunarizin are being studied; Aspartase (caspase) inhibitors, etc., but the fact is that there are no practical drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for preventing or treating hearing loss
  • Pharmaceutical composition for preventing or treating hearing loss
  • Pharmaceutical composition for preventing or treating hearing loss

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0053] Embodiment 1: According to the effect analysis of compound preparation of the present invention on hearing function and vestibular function

[0054] Preparation of compound preparation

[0055] Cilostazol (CS, SK Chemicals) and Ginkgo biloba extract (GbE, SK Chemicals) were mixed in a weight ratio of 5:4 and dissolved in 0.5% (w / v) carboxymethylcellulose sodium (CMCNa, Sigma) in an aqueous solution to prepare a composite preparation (hereinafter referred to as renexin) at a concentration of 18 mg / mL.

[0056] Application of sample

[0057] 52 SD (Sprague-Dawley) rats (200-250 g) aged 8-10 weeks were divided into the following 6 groups, and each drug was administered as follows.

[0058] -The first group: normal control group (n=3);

[0059] -The second group: cisplatin (CDDP) administration group alone (n=13);

[0060] -The third group: ranashin+CDDP administration group (n=12);

[0061] - The fourth group: Ginkgo biloba extract+CDDP administration group (n=12); ...

Embodiment 2

[0078] Example 2: Morphological evaluation of auditory and vestibular hair cells administered according to the compound formulation of the present invention

[0079] Morphological evaluation of the middle and bottom

[0080] The rats in each group of Example were anesthetized, and then their temporal bones were removed. Under a dissecting microscope, in the cochlea The round window (round window) and oval window (oval window) were drilled, and the perilymphatic space (perilymphatic space) was perfused with 4% glutaraldehyde (EMgrade, place of origin, Inc.CA, USA) with a Pasteur pipette. Each sample was then fixed in 4% glutaraldehyde solution for 24 hours. The surface of the cochlea and the perilymphatic space were washed three times with phosphate buffered solution (PBS), perfused with 1% osmium tetroxide, and placed on a tissue rotator for 15 minutes. Then, the sample was washed 3 times with PBS, the bony capsule of the cochlea was removed under a dissecting microscope...

Embodiment 3

[0092] Embodiment 3: Analysis of the in vitro effect of the compound preparation of the present invention on CDDP-induced cytotoxicity

[0093] Confirmation of CDDP-induced cytotoxicity

[0094] In order to confirm CDDP-induced cytotoxicity, the auditory cell line (HEI-OC1 (ATCC, USA) was cultured at 33°C with 10% CO2 in Dulbecco's essential medium (DMEM, Dulbecco's minimum essential medium) was cultured. The cultured cells were divided into 96-well plates at a concentration of 3000 cells / well, and then 20 μM cisplatin was added for culture. When cultivating the first 0, 12, 24 and 48 hours, 20 μl of MTS solution was added to each well, and the culture was continued for 4 hours, and then the absorbance of formazan was measured at 490 nm by a fully automatic quantitative drawing microplate reader, so as to determine the proportion of surviving cells.

[0095] The measurement results are shown in Figure 8 . Such as Figure 8 As shown, according to the treatment with cisplati...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating hearing loss, containing cilostazol and a ginkgo leaf extract as active ingredients. The pharmaceutical composition can effectively prevent or treat noise-induced hearing loss or ototoxic hearing loss by inhibiting the apoptosis of hair cells due to the generation of reactive oxygen species (ROS).

Description

technical field [0001] The invention relates to a pharmaceutical composition for preventing or treating hearing impairment containing cilostazol and ginkgo leaf extract as active ingredients. Background technique [0002] Hearing impairment is a hearing abnormality caused by various reasons. It refers to the state of hearing loss or loss. The ear is composed of the outer ear (auricle to tympanic membrane), middle ear (tympanic membrane to cochlear entrance) and inner ear (inside the cochlea). As long as there is a problem in one place, it will cause hearing loss. Hearing impairment is divided into hearing impairment caused by damage to the outer ear and middle ear (conductive hearing impairment) and auditory nerve impairment caused by damage to the inner ear and auditory nervous system (sensorineural hearing impairment). Hearing impairment can be restored by treating the above-mentioned damages, but the hearing impairment caused by damage to the inner ear and the auditory n...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4709A61K36/16A61P27/16
CPCA61K31/4709A61K36/16A61P27/16A61K2300/00
Inventor 柳根镐韩蕙英李素英
Owner SK CHEM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com